Clinical evaluation demonstrates bevacizumab efficacy for brain radiation necrosis in nonsquamous nonsmall cell lung cancer, highlighting an effective therapeutic option.
•The incidence of brain radiation necrosis is increasing in NSCLC patients undergoing radiotherapy for brain metastases.•[11C] methionine–PET and MRS are valuable tools for diagnosing brain radiation necrosis.•Bevacizumab is an effective treatment for brain radiation necrosis in patients with nonsquamous NSCLC. •The incidence of brain radiation necrosis is increasing in NSCLC patients undergoing radiotherapy for brain metastases.•[11C] methionine–PET and MRS are valuable tools for diagnosing brain radiation necrosis.•Bevacizumab is an effective treatment for brain radiation necrosis in patients with nonsquamous NSCLC.
No takes yet. Share an insight, caveat, or question.
Shibahara et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: